Display options
Cite
Columbo M. Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast. Asthma Res Pract. 2017;3:3doi: 10.1186/s40733-017-0031-4.
Columbo, M. (2017). Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast. Asthma research and practice, 33. https://doi.org/10.1186/s40733-017-0031-4
Columbo, Michele. "Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast." Asthma research and practice vol. 3 (2017): 3. doi: https://doi.org/10.1186/s40733-017-0031-4
Columbo M. Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast. Asthma Res Pract. 2017 Apr 17;3:3. doi: 10.1186/s40733-017-0031-4. eCollection 2017. PMID: 28428890; PMCID: PMC5393032.
Copy Download .nbib Format: NLM
Share it on

Asthma Res Pract. 2017 Apr 17;3:3. doi: 10.1186/s40733-017-0031-4. eCollection 2017.

Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast.

Asthma research and practice

Michele Columbo

Affiliations

  1. Division of Allergy and Immunology, Bryn Mawr Hospital, Bryn Mawr, PA USA.

PMID: 28428890 PMCID: PMC5393032 DOI: 10.1186/s40733-017-0031-4

Abstract

BACKGROUND: Little is known about asthma in the elderly as most studies of this condition have not included this patient group. It is unclear whether leukotriene antagonists benefit older asthmatics. We studied the effect of adding montelukast to the asthma treatment of elderly subjects.

METHODS: Twenty-five subjects 65 years old and older with asthma were evaluated at week 0, 1, 5, 9, 13, and 17. Each subject received montelukast 10 mg and placebo each for 8 weeks in a cross-over design.

RESULTS: Montelukast for 4 or 8 weeks did not significantly affect ACT, daily symptom scores, number of puffs of albuterol, spirometric values, peripheral blood eosinophils, or serum IgE vs. baseline or placebo. Similar results were obtained when analyzing subgroups of patients with lower ACT, lower FEV1, and higher eosinophils.

CONCLUSIONS: In this study of elderly asthmatics, montelukast had no effect on asthma symptoms, number of puffs of albuterol, spirometric values, peripheral blood eosinophils or serum IgE. These results will require confirmation in larger patient cohorts and in patients with uncontrolled asthmatic symptoms.

Keywords: Asthma; Elderly; Montelukast

References

  1. J Asthma. 2012 Jun;49(5):530-4 - PubMed
  2. Ann Allergy Asthma Immunol. 2000 Feb;84(2):217-25 - PubMed
  3. N Engl J Med. 1986 Aug 21;315(8):480-4 - PubMed
  4. Ann Allergy Asthma Immunol. 2002 Apr;88(4):401-9 - PubMed
  5. Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1562-7 - PubMed
  6. Am J Respir Crit Care Med. 1999 Dec;160(6):1862-8 - PubMed
  7. Respir Med. 2013 May;107(5):785-7 - PubMed
  8. J Allergy Clin Immunol. 2011 Sep;128(3 Suppl):S4-24 - PubMed
  9. Arch Intern Med. 1998 Jun 8;158(11):1213-20 - PubMed
  10. Allergy Asthma Immunol Res. 2015 Sep;7(5):440-8 - PubMed
  11. Ann Intern Med. 1999 Mar 16;130(6):487-95 - PubMed
  12. Allergy Asthma Clin Immunol. 2016 Mar 11;12:15 - PubMed

Publication Types